Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and in today’s episode, we’re exploring new research connecting cholesterol imbalance to depression in obesity, Eli Lilly’s latest biotech acquisition aimed at strengthening its neuroscience pipeline, and Cambrex’s $120 million investment to expand API manufacturing capacity across its US sites.

• A new study published in Diabetology & Metabolic Syndrome reports that adults with obesity who have a high non-HDL to HDL cholesterol ratio face a greater risk of depression. Researchers believe that elevated lipid levels may worsen inflammation and disrupt neurotransmitter function, contributing to mood disorders. The findings highlight the need for integrated care models that address both metabolic and mental health, an emerging focus in preventive medicine.
• In business news, Eli Lilly has signed a definitive agreement to acquire Aderum Biotechnologies, a biotech specializing in novel therapies for neurodegenerative diseases. The acquisition aligns with Lilly’s broader push into neuroscience, adding Aderum’s proprietary platform for repairing mitochondrial dysfunction, an area of growing interest in conditions like Alzheimer’s and Parkinson’s. Analysts say the move could help diversify Lilly’s pipeline beyond diabetes and obesity as the company continues its expansion into brain health.
• Lastly, in manufacturing, Cambrex is investing $120 million to expand its active pharmaceutical ingredient production capacity at is Charles City, IA facility. The company says the expansion will help meet rising demand for complex small-molecule APIs and reinforce domestic supply chain resilience amid global sourcing challenges.

From new insights into the metabolic roots of depression to strategic biotech acquisitions and manufacturing growth, these stories underscore how science, business, and infrastructure continue to drive pharma’s evolution.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.